BallsM. It’s time to include harm to humans in harm–benefit analysis — But how to do it, that is the question. Altern Lab Anim2022; 49: 182–196.
3.
NeuhausWReininger-GutmannBRinnerB, et al.The rise of Three Rs centres and platforms in Europe. Altern Lab Anim2022; 50: 90–120.
4.
RivasMReinaM. Determination of the microinjected cytosolic concentration by using mathematical models of fluid dynamics. Altern Lab Anim2022; 50: 136–145.
5.
RoncaglioniALombardoABenfenatiE. The VEGAHUB Platform: The philosophy and the tools. Altern Lab Anim2022; 50: 121–135.
6.
PereraDSoysaPWijeratneS. A comparison of mesenchymal stem cell-derived hepatocyte-like cells and HepG2 cells for use in drug-induced liver injury studies. Altern Lab Anim2022; 50: 146–155.
7.
SonawaneAVadlooriBPoosalaS, et al.Advances in animal models and cutting-edge research in alternatives: Proceedings of the Second International Conference on 3Rs Research and Progress, Hyderabad, 2021. Altern Lab Anim2022; 50: 156–171.